TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your Rights - NEO

Newsfile 24-Jan-2023 10:20 PM

New York, New York--(Newsfile Corp. - January 24, 2023) - Levi & Korsinsky, LLP notifies investors in NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO) of a class action securities lawsuit.

The lawsuit on behalf of NeoGenomics investors has been commenced in the the United States District Court for the Southern District of New York. Affected investors purchased or otherwise acquired certain NeoGenomics, Inc. securities between February 27, 2020 and April 26, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35913&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/152429_486265_logo.jpg



Cannot view this video? Visit:
https://www.youtube.com/watch?v=r-WSY0R1YYY

NeoGenomics, Inc. NEWS - NEO NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in NeoGenomics during the relevant timeframe, you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35913&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152429

Image for Press Release 1626568